JP2011502513A - 癌患者における診断用途のための方法および組成物 - Google Patents

癌患者における診断用途のための方法および組成物 Download PDF

Info

Publication number
JP2011502513A
JP2011502513A JP2010533204A JP2010533204A JP2011502513A JP 2011502513 A JP2011502513 A JP 2011502513A JP 2010533204 A JP2010533204 A JP 2010533204A JP 2010533204 A JP2010533204 A JP 2010533204A JP 2011502513 A JP2011502513 A JP 2011502513A
Authority
JP
Japan
Prior art keywords
patient
cancer
genes
therapy
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010533204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502513A5 (OSRAM
Inventor
ダニエル エス． チェン，
コーター， ジェニファー ル
トーマス ディー． ウー，
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2011502513A publication Critical patent/JP2011502513A/ja
Publication of JP2011502513A5 publication Critical patent/JP2011502513A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010533204A 2007-11-09 2008-11-05 癌患者における診断用途のための方法および組成物 Withdrawn JP2011502513A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98688407P 2007-11-09 2007-11-09
PCT/US2008/082456 WO2009061800A2 (en) 2007-11-09 2008-11-05 Methods and compositions for diagnostic use in cancer patients

Publications (2)

Publication Number Publication Date
JP2011502513A true JP2011502513A (ja) 2011-01-27
JP2011502513A5 JP2011502513A5 (OSRAM) 2012-12-27

Family

ID=40342593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010533204A Withdrawn JP2011502513A (ja) 2007-11-09 2008-11-05 癌患者における診断用途のための方法および組成物

Country Status (13)

Country Link
US (2) US20090123930A1 (OSRAM)
EP (1) EP2222874A2 (OSRAM)
JP (1) JP2011502513A (OSRAM)
KR (1) KR20100095571A (OSRAM)
CN (1) CN101910416A (OSRAM)
AU (1) AU2008324782A1 (OSRAM)
BR (1) BRPI0817158A2 (OSRAM)
CA (1) CA2703258A1 (OSRAM)
IL (1) IL205246A0 (OSRAM)
MX (1) MX2010005057A (OSRAM)
RU (1) RU2010123381A (OSRAM)
WO (1) WO2009061800A2 (OSRAM)
ZA (1) ZA201002808B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015180879A (ja) * 2010-07-19 2015-10-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌治療への応答可能性の増大した患者を同定する方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201510152RA (en) * 2009-07-13 2016-01-28 Genentech Inc Diagnostic methods and compositions for treatment of cancer
MX2012002909A (es) * 2009-09-17 2012-04-19 Hoffmann La Roche Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
CN103109189A (zh) * 2010-07-19 2013-05-15 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法
SG10201604497UA (en) * 2011-06-02 2016-07-28 Almac Diagnostics Ltd Molecular Diagnostic Test For Cancer
AU2013207778B2 (en) * 2012-01-13 2017-10-12 Genentech, Inc. Biological markers for identifying patients for treatment with VEGF antagonists
CN104364655A (zh) * 2012-06-26 2015-02-18 霍夫曼-拉罗奇有限公司 贝伐单抗组合疗法用于治疗乳腺癌的血浆生物标志物
CA2893033A1 (en) * 2012-12-03 2014-06-12 Almac Diagnostics Limited Molecular diagnostic test for cancer
WO2015050500A1 (en) 2013-09-17 2015-04-09 Agency For Science, Technology And Research Multigene assay for prognosis of renal cancer
GB201409479D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
EP3230498B1 (en) * 2014-12-09 2023-01-18 Merck Sharp & Dohme LLC System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
KR101903522B1 (ko) * 2015-11-25 2018-11-23 한국전자통신연구원 다차원 건강데이터에 대한 유사사례 검색 방법 및 그 장치
US20250155442A1 (en) * 2023-11-09 2025-05-15 Sun Jet Biotechnology Inc. Apolipoprotein a-ii biomarkers for detecting and monitoring cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027216A1 (en) * 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
US8691506B2 (en) * 2005-04-13 2014-04-08 Oncotest Gmbh Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds
WO2007123722A2 (en) * 2006-03-31 2007-11-01 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015180879A (ja) * 2010-07-19 2015-10-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌治療への応答可能性の増大した患者を同定する方法

Also Published As

Publication number Publication date
AU2008324782A1 (en) 2009-05-14
RU2010123381A (ru) 2011-12-20
US20090123930A1 (en) 2009-05-14
KR20100095571A (ko) 2010-08-31
EP2222874A2 (en) 2010-09-01
WO2009061800A3 (en) 2009-07-16
CA2703258A1 (en) 2009-05-14
ZA201002808B (en) 2011-07-27
CN101910416A (zh) 2010-12-08
US20110151468A1 (en) 2011-06-23
IL205246A0 (en) 2010-12-30
MX2010005057A (es) 2010-05-19
WO2009061800A2 (en) 2009-05-14
BRPI0817158A2 (pt) 2015-04-14

Similar Documents

Publication Publication Date Title
AU2009329994B2 (en) Methods and compositions for diagnostic use in cancer patients
RU2739942C2 (ru) Терапевтические, диагностические и прогностические способы для рака мочевого пузыря
JP6095367B2 (ja) 癌治療のための診断方法および組成物
US20090123930A1 (en) Methods and compositions for diagnostic use in cancer patients
JP6664323B2 (ja) 神経膠芽腫を治療するための診断方法及び組成物
JP5606537B2 (ja) 癌患者における診断使用のための方法及び組成物
US20100029491A1 (en) Methods and compositions for diagnostic use for tumor treatment
US20120015049A1 (en) Microrna biomarker in cancer
WO2011153224A2 (en) Diagnostic methods and compositions for treatment of cancer
HK1170542B (en) Methods and compositions for diagnostics use in cancer patients
BR112017012553B1 (pt) Método de tratamento de um paciente que sofre de um câncer, método para o diagnóstico de um câncer, método para o prognóstico de um paciente que sofre de câncer, método para determinar se um paciente com um câncer e método para otimizar a eficácia terapêutica de uma terapia anticâncer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111020

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20130220

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20130305